Introduction: Correct use of inhalation devices is critical for optimal drug delivery to the lower
consensus on potential handling errors for each device from ten independent respiratory device experts. In Round 1, advisors listed potential errors with the devices. In Round 2, a severity rating was assigned to each error based on erroneous device handling negatively affecting functionality and treatment effectiveness (error [score 0-3]; potentially critical [4] [5] [6] [7] ; critical [8] [9] [10] ). In Round 3, advisors revised their ratings based on the group scores and voted on whether to accept the median severity score as the consensus in Round 4.
Results: A total of 29 potential errors for Spiromax and 31 for Turbuhaler were identified in Round 1. After Round 4, consensus was reached for 69% of the Spiromax errors and 94% of the Turbuhaler errors. After completion of the Delphi process, some anomalies were identified in the list of handling errors, which were then investigated with the panel via teleconferences. After teleconferences to discuss discrepancies in the results, there were 22 errors for Spiromax (four critical, 12 potentially critical, and six errors) and 27 for Turbuhaler (nine critical, 14 potentially critical, and four errors). Not inhaling through the mouthpiece, exhaling into the device, and incorrect mouth positioning were identified as critical errors for both devices.
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INTRODUCTION
Respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) are routinely managed using inhaled bronchodilators and corticosteroids [1, 2] . However, the medication must reach the receptors in the lower airways to exert its effect. To ensure this happens, correct use of the inhaler device is critical for optimal drug delivery [3] . Patient-related factors such as poor adherence and inhaler handling errors have a negative impact on asthma control [4] . Studies have shown that poor inhaler technique is common and inhaler use is often highly suboptimal [5] . Estimates of improper inhaler use range from 20% to 82% of patients [4, [6] [7] [8] [9] . There is increasing evidence in support of the claim that correct inhaler technique is fundamental for effective therapy and asthma management [5, 10, 11] . Errors in the use of inhalers have been shown to have serious effects in terms of the management of the disease [6, 8, 9] . Poor inhaler technique in patients with asthma is associated with increased hospitalization, more emergency department visits, increased use of oral corticosteroids and antimicrobials, and poorer asthma control [6, 8, 9] . Some errors are device-independent and include not breathing out before actuation of the device [12] . Although correct inhaler technique involves some common steps for all devices, the optimal inhalation pattern differs between devices [3, 13] . Inhalers that are perceived as difficult to use are usually associated with poor inhalation technique and low treatment adherence, leading to worsening in asthma control [14] .
As such, the technical characteristics of an inhaler device can determine how well it is handled, and consequently, how often it is correctly used. An inhaler that is easy to use, intuitive, and preferred by the patient could ultimately improve adherence [14] [15] [16] .
In patients with inadequately controlled asthma, the combination therapy involving an inhaled corticosteroid (ICS) and a long-acting b2 agonist (LABA) is a recommended therapy [17] . The fixed-dose combination of the ICS/ LABA, budesonide/formoterol (BF), has proven to be an effective therapy by improving pulmonary function and asthma control [1, 2] in patients with asthma and COPD. DuoResp is an established tool for reaching a consensus on a complex problem in a highly objective way [19] [20] [21] . In the Delphi process, a peer group of experts work together anonymously to reach consensus on a complex problem as objectively as possible.
The aims of this Delphi process study were to independently establish what is considered an error (for optimal drug delivery) when handling empty versions of DuoResp Spiromax or Symbicort Turbuhaler dry powder inhalers and to assign a level of severity to each of these errors.
METHODS

Study Procedures
This study was conducted by InterPhase Consult, an independent strategic consulting firm, on behalf of Teva Pharmaceuticals Inc. 
Advisor Selection
Fifteen European advisors were identified.
Advisors were invited to participate until 10 had accepted, per the recommendations of Delbecq et al. (1975) for panel selection when performing a Delphi methodology study [22] .
Please refer to the Appendix in the supplementary material for additional details on the advisors selection. reasoning behind the score they assigned for each error.
Round 3 Advisors were given an individualized report
showing their responses relative to the consolidated group severity scores and were
given the opportunity to re-evaluate their scores and revise them if they wished. If a consensus was not achieved for C90% of errors for each device, a fourth round was to be conducted.
Round 4
Advisors were provided with a list of all errors grouped within their corresponding categories as determined by the median score from Round 3. They were then asked to agree or disagree with the error category for each error based on the median error severity ranking from Round 
Post-hoc Study Amendment
In a post hoc study amendment, advisors were asked to participate in a series of teleconferences to discuss and refine the output from the Delphi process. A summary of the consensus from the calls was subsequently approved by the participating advisors.
Data Analysis
Scores obtained for each error in Rounds 2 and 3
were analyzed using descriptive statistics and median scores were calculated using Microsoft 
RESULTS
Conduct of the Study
Ten advisors participated in this study (Table S1 ). Full consensus was not reached for C90% of the errors after Round 3; a fourth round was conducted. Some changes were made to the wording and design of the questionnaire following Round 1 to emphasize the intended meaning and definition of a handling error.
Identification of Errors Using the Delphi
Process (Rounds 1-4)
Round 1
A total of 29 potential errors were identified for Spiromax in Round 1 and 31 were identified for
Turbuhaler (data on file, Teva Pharmaceuticals and InterPhase Consult).
Rounds 2 and 3
None of the errors was deemed to be invalid by seven or more advisors in Round 2 and all were retained.
Median severity scores were assigned to each of the errors and did not change significantly between Rounds 2 and 3 ( Table 1) . A critical severity score was given on fewer occasions for errors in using Spiromax compared with
Turbuhaler.
The errors considered by the advisors to be most critical (median severity score of C9) when using Turbuhaler were 'not inhaling through the mouthpiece (e.g., nose)', 'difficulty/failure to remove the cap prior to usage', 'forgetting to load the device prior to each dosage', and 'exhaling into the device'. The error 'forgetting to load the device prior to each dosage' was assigned to the critical error category by all ten advisors; nine advisors put 'exhaling into the device', 'not inhaling through the mouthpiece (e.g., nose)', 'red grip is only rotated fully in one direction prior to using the device', and 'holding the mouthpiece instead of the barrel when twisting the red grip' in the critical error category.
For Spiromax, the errors considered to be most critical were 'not inhaling through the mouthpiece (e.g., nose)' and 'failure to read the dose indicator correctly, potentially leading to using an empty device'. None of the errors were classified as being critical by all 10 advisors; eight advisors classed 'not inhaling through the mouthpiece (e.g., nose)' as a critical error.
After Round 3, consensus was reached for 38% of the errors for Spiromax and 68% of the errors for Turbuhaler.
Round 4
In Round 4, the median severity scores from Round 3 were accepted as the consensus for an were removed, as they were not thought to be valid handling errors for the device, and two errors that had originally only been identified for Spiromax were added (not holding the breath for long enough following inhalation; unable to/forgetting to breathe out fully prior to inhalation).
Final Outcome
Following the teleconferences, the number of potential handling errors was finalized as 22 for Spiromax and 27 for Turbuhaler ( Fig. 3 ). In comparison, the 27 potential handling errors for Turbuhaler comprised nine critical errors, 14 potentially critical errors, and four non-critical errors (Table 1 ; Fig. 3 ).
DISCUSSION
Despite the availability of a wide variety of medications, a significant portion of patients with asthma and COPD remain uncontrolled [14] [15] [16] . The correct use of an inhaler device is crucial for optimal drug delivery. As such, the inhaler device itself plays an important and active role in asthma management. It is therefore important to have devices which are intuitive to use and to train patients. Findings from this study are in agreement with outcomes reported in two independent device mastery studies among healthy Finnish volunteers and healthcare practitioners (HCPs) in Australia. In healthy adult Finnish volunteers [23] and Australian HCPs [24] , Spiromax was associated with higher levels of device mastery and fewer errors by intuitive use/no instructions and after reading the patient information leaflet compared with Turbuhaler.
Training patients in inhaler use is a core component of good clinical practice [25] .
Consequently, providing HCPs with an inhaler
that is less prone to device handling errors and easy to use and teach patients could potentially reduce the number of device handling errors and ultimately improve asthma control. Results from this study highlight specific errors that could potentially be committed using Spiromax or Turbuhaler. Two errors for Turbuhaler received the maximum median severity score of 10; these were 'not inhaling through the mouthpiece (e.g., nose)' and 'difficulty/failure to remove the cap prior to usage'. A number of errors regarding priming of the device were classified as critical for Turbuhaler (which were not identified for Spiromax). These included, 'forgetting to load the device prior to each dosage', 'failing to fully rotate the red grip', 'failure to read the dose indicator correctly, potentially leading to using an empty device', and 'red grip is only rotated fully in one direction prior to using the device'. The highest median severity score for a Spiromax error was 9.5 for 'not inhaling through the [8, 27] .
Matching the correct patient with the correct inhaler is now thought to be essential when prescribing an inhaler that a patient can and will use correctly at every use [28, 29] . The Delphi process methodology was deemed most suitable for this study because it is an established tool for reaching consensus on a complex problem as objectively as possible. It has been proven to be effective for reaching a consensus when factual data do not exist or cannot easily be obtained, or when the problem is so subjective that an individual may give an opinion that conforms to those of other participants rather than maintaining their own critical opinion [19, 30] . 
